Possible trimethoprim/sulfamethoxazole-induced aseptic meningitis

The Annals of Pharmacotherapy
Roxane Therrien

Abstract

To report a case of trimethoprim/sulfamethoxazole (TMP/SMX)-induced aseptic meningitis. An 18-year-old woman diagnosed with acute myeloid leukemia was admitted for a bone marrow transplant. She had already attained remission with daunorubicin, thioguanine, and high-dose cytarabine. A routine lumbar puncture performed on admission revealed an abnormally elevated leukocyte count, and meningitis was suspected. The patient had been taking TMP/SMX (trimethoprim 120 mg) twice daily on Monday, Tuesday, and Wednesday for the past 3 months; no other medication was being used. Upon examination, the patient mentioned having had headaches for the past few weeks. Since viral, bacterial, and fungal cultures were negative, a diagnosis of aseptic meningitis was made. According to the Naranjo probability scale, TMP/SMX was a possible cause of the aseptic meningitis. Eleven days after discontinuation of TMP/SMX, lumbar puncture results had returned to normal. Many drugs have been associated with aseptic meningitis. Antibiotics are often linked with aseptic meningitis, with TMP/SMX being the most frequently associated antibiotic. Many cases of TMP/SMX-induced aseptic meningitis have been reported, while few cases have been reported with trimethop...Continue Reading

References

Jun 1, 1992·The Annals of Pharmacotherapy·J S Marinac
Nov 23, 1984·JAMA : the Journal of the American Medical Association·S J Derbes
Aug 1, 1981·Clinical Pharmacology and Therapeutics·C A NaranjoD J Greenblatt
Sep 1, 1995·Archives of Disease in Childhood·D PashankarA Robinson
Sep 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M S HarrisonC A Kauffman
Apr 1, 1994·Cancer Treatment Reviews·M K Tuxen, S W Hansen
Jun 17, 1999·Archives of Internal Medicine·G Moris, J C Garcia-Monco
Mar 30, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S JollesC Leighton
Oct 29, 2000·Seminars in Neurology·H A Rotbart
Feb 15, 2001·The Pediatric Infectious Disease Journal·C L PeaseS L Kaplan
May 23, 2001·Leukemia·H van den BergM D van de Wetering
May 29, 2003·Current Drug Targets. Immune, Endocrine and Metabolic Disorders·Eustachio NettisAlfredo Tursi
Jun 24, 2003·Archives of Disease in Childhood·H El BashirR Booy

❮ Previous
Next ❯

Citations

Sep 10, 2010·The American Journal of Emergency Medicine·Michael D Repplinger, Peter M Falk
Sep 23, 2014·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Karen E BrunerKevin M White
Sep 4, 2013·International Journal of STD & AIDS·D RowleyF Lyons
Jan 5, 2010·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Takafumi NaitohYasuhisa Shinomura

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
M S HarrisonC A Kauffman
JAMA : the Journal of the American Medical Association
S J Derbes
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Marie A Chisholm-BurnsChristina A Spivey
© 2021 Meta ULC. All rights reserved